In a mouse model of MASH, rifaximin was found to mitigate MASH by restoring gut, reversing intestinal barrier dysfunction, and modulating the expression of peroxisome proliferator-activated receptor (PPAR)α and PPARγ in the liver [97]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.